



IRAS Ref:

HEALTHY CONTROL PARTICIPANT INFORMATION SHEET

Study Title: Visual Function in Retinal Degeneration

Chief Investigator: Professor Robert E MacLaren

We would like to invite you to take part in our research study. Before you decide, it is important that you understand why the research is being done and what it would involve for you. Please take time to read this information, and discuss it with others if you wish.

If there is anything that is not clear, or, if you would like more information, please ask us.

What is the purpose of the study?

The primary purpose of this study is to assess the usefulness and effectiveness of current and new visual assessments for use in patients with inherited retinal degeneration. The results will enable us to determine which tests are the most suitable for patients with a particular disease and disease stage. These tests are already approved tests but have not been used in specific types of retinal degeneration.

Why have I been invited?

You have been invited to take part in this study because you have expressed interest in taking part as a control. A member of the research team will go through this information with you and answer any questions to help you decide if you would like to take part. We are aiming to involve 40 participants with retinal degeneration and 40 healthy controls with no known visual problems other than glasses prescription if required.

Do I have to take part?

It is up to you to decide whether or not to take part. If you decide to take part, you will be given this information sheet to keep and be asked to sign a consent form. If you decide to take part, you are still free to withdraw at any time and without giving a reason.

What will happen to me if I decide to take part?

You will be invited to attend at a time that is convenient for you to conduct a series of vision tests. All the tests will take place within the Oxford Eye Hospital.

<u>Control Participant Information Sheet</u>
Study Short Title: Visual Function in Retinal Degeneration

Version/Date: 3.0 21/01/22

Ethics Ref:

Chief Investigator: Professor Robert E MacLaren

The study vision assessments include:

- Three questionnaires about your vision, how you feel about your vision and your quality of life
- A glasses correction check
- Visual acuity tests that involves reading letters on a letter chart
- Visual field tests that involves assessing the area extent of your vision.
- Visual field tests after 20 minutes of allowing the eyes to adjust to very low light

All tests are CE marked and will be used for their intended purposes – assessing visual function.

They study tests are divided into two parts, part 1 and part 2. Each take about 60 minutes. Depending on time and availability, you may only be required to complete just one part. If you complete both parts the study time will be 120 minutes. There will be opportunities for breaks at any point. If you are a friend or family member of a patient participant who is taking part in the study, we will aim to complete all the study tests for both participants on the same day. It is not possible to undertake the study assessments simultaneously but we will plan a schedule to suit everyone, to try and minimise any waiting time.

In order to achieve the best results, in some cases, the eyes have to be adjusted to the darkness, a 20-minute period of sitting in the dark is required prior to performing the test, this is included in the 120-minute study testing time.

If you require glasses correction for distance vision is it helpful if you bring these to the study although not essential. If you wear contact lenses, you are still eligible to participate in the study but the contact lenses will need to be removed during the study assessments.

A small subset of participants will be invited to repeat some of the study tests again, within 4 weeks of the initial study visit. This is to enable us to investigate the variability in results.

What will happen if I do not want to carry on?

You have a right to withdraw from the study at any time, without giving a reason, but we will keep information about you that we already have.

What are the possible risks of taking part?

There are no direct risks to taking part. This is because the vision tests are non-invasive and do not pose any hazards. If you become tired during testing, you will have the opportunity to stop and rest before

IRAS Ref:

<u>Control Participant Information Sheet</u>
Study Short Title: Visual Function in Retinal Degeneration

Version/Date: 3.0 21/01/22

Ethics Ref:

Chief Investigator: Professor Robert E MacLaren

continuing with testing. There is a very small chance of finding an unexpected abnormal result such as unknown reduced vision.

What will happen if you find an abnormal result?

If an abnormal result e.g. reduced vision is detected, the researcher will recommend you get an eye test with your optometrist. With your consent, the researcher will write to your GP to inform them of the recommendation as well as give you a copy of the letter, we recommend you take this with you to your optometrist eye test appointment.

What are the possible benefits of taking part?

There are no direct benefits of taking part in this research project. However, by taking part, you will be contributing to improving our understanding on how to best measure vision in people affected by a retinal disease. The outcomes of this study may play a role in helping patients in the future, and in the development of effective treatments or services.

Will my part in this study be kept confidential?

All information, which is collected, about you during the course of the research will be kept strictly confidential. If you decide to participate, only initials and an ID number will identify you. Only the consent form will contain your name and email, this will be stored securely in a locked filing cabinet, and will only be accessible by authorised personnel. The study will comply with the Data Protection Act 2018. The data will be archived in a secure facility for 3 years from the end of the study.

Responsible members of the University of Oxford and the Oxford University Hospitals NHS Foundation Trust may be given access to data for monitoring and/or audit of the study to ensure that the research is complying with applicable regulations.

Will I be reimbursed for taking part?

No, there will be no reimbursement.

What will happen to my data?

UK Data protection regulation requires that we state the legal basis for processing information about you. In the case of research, this is 'a task in the public interest.' The University of Oxford, based in the United Kingdom is the data controller and is responsible for looking after your information and using it properly. We will keep identifiable information about you for three years after the study has finished. This excludes any research documents with personal information, such as consent forms, which will be held securely at the University of Oxford for also three after the end of the study.

Control Participant Information Sheet Version/Date: 3.0 21/01/22 Study Short Title: Visual Function in Retinal Degeneration Ethics Ref: IRAS Ref:

Chief Investigator: Professor Robert E MacLaren

UK Data protection regulation provides you with control over your personal data and how it is used. When you agree to your information being used in research, however, some of those rights may be limited in order for the research to be reliable and accurate. Further information about your rights with respect to your personal data is available at

https://compliance.web.ox.ac.uk/individual-rights

What will happen to the results of this study?

At the end of the study the anonymised results, will be analysed and published in the medical literature and presented at conferences. Anonymised research data gathered may contribute to the fulfilment of an educational requirement (e.g. an MSc thesis). You will not be identified in any report/publication.

If you would like to be notified about the results of the study, please indicate this on the consent form.

What if there is a problem?

The University of Oxford, as Sponsor, has appropriate insurance in place in the unlikely event that you suffer any harm as a direct consequence of your participation in this study. Given the observational and non-invasive nature of this study, it is highly unlikely that you will suffer harm by taking part.

If you wish to complain about any aspect of the way in which you have been approached or treated during the course of this study, you should contact Laura Wood at trials@eye.ox.ac.uk or 01865 231122, or you may contact the University of Oxford Research Governance, Ethics & Assurance (RGEA) office on 01865 616480, or the director of RGEA, email ctrg@admin.ox.ac.uk.

The Patient Advisory Liaison Service (PALS) is a confidential NHS service that can provide you with support for any complaints or queries you may have regarding the care you receive as an NHS patient. You will be able to contact the Patient Advice and Liaison Service (PALS) in the first instance (01865 221473). PALS is unable to provide information about this research study.

Who is organising and funding the study?

The study is being organised by Laura Taylor from the Nuffield Laboratory of Ophthalmology and sponsored by the University of Oxford. The study is funded by the NIHR Research for Patient Benefit tier 3 fund.

Who has reviewed the study?

All research in the NHS is looked at by an independent group of people, called a Research Ethics Committee, to protect participants' interests. This study has been reviewed and given favourable opinion by Black Country Research Ethics Committee.

<u>Control Participant Information Sheet</u>

Study Short Title: Visual Function in Retinal Degeneration

Version/Date: 3.0 21/01/22

Ethics Ref:

Chief Investigator: Professor Robert E MacLaren

Ethics Ref: IRAS Ref:

Further information and contact details:

Laura Taylor Specialist Research Optometrist

Oxford Eye Hospital, JR Hospital West Wing LG1

Headington, Oxford OX3 9DU

Email: trials@eye.ox.ac.uk

Phone: 01865 231122

Thank you for reading this information sheet

Control Participant Information Sheet
Study Short Title: Visual Function in Retinal Degeneration
Chief Investigator: Professor Robert E MacLaren

Version/Date: 3.0 21/01/22 Ethics Ref: IRAS Ref: